An open-label study of Xeloda [capecitabine] plus radiotherapy on overall tumor response rate in treatment-naive patients with locally advanced squamous cell cancer of the cervix.

Trial Profile

An open-label study of Xeloda [capecitabine] plus radiotherapy on overall tumor response rate in treatment-naive patients with locally advanced squamous cell cancer of the cervix.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2010

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 27 Feb 2010 Status changed from recruiting to completed as reported by Roche record.
    • 27 Feb 2010 Planned number of patients changed from 59 to 60 as reported by Roche record.
    • 23 Feb 2010 Planned number of patients changed from 100 to 59 as reported by Roche record..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top